Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
•
Urology
Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?
Related Questions
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
What is your approach to muscle-invasive bladder cancer in a patient who is ineligible for surgery and radiotherapy?
For patients with T1 bladder cancer who have severe obstructive uropathy/hydronephrosis, do you treat as high risk stage I disease with RC, or clinically upstage and manage as a more locally advanced disease (NAC+RC)?
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
Would you offer neoadjuvant chemotherapy prior to trimodality therapy in a fit patient who refuses surgery for muscle-invasive bladder cancer?
